I think the decline in bariatric surgery becomes a grave problem when patients with severe obesity, those with a BMI of 35+ with serious comorbidities, without understanding that surgery may be infinitely more effective for them, said DeBarros
In agreement with this, we recently showed that GLP-1-mediated delivery of the PPAR/ co-agonist tesaglitazar (Tesa) decreases body weight and food intake with increased efficacy compared with GLP-1R agonism in DIO mice 26
Decisions about continuation, changes, or discontinuation, which Willow does not override
The company plans to release interim Phase 2 data for the treatment of obesity in Q2 2025 and final data in Q4 2025
Patients taking tirzepatide should be informed of the potential serious adverse events
You dont have to adjust your diet too much or worry about tracking micronutrients